Literature DB >> 3191141

The reaction mechanism of bovine kidney biliverdin reductase.

E Rigney1, T J Mantle.   

Abstract

The steady-state kinetics of biliverdin reductase can be studied in detail at pH 9 as under these conditions the Km for biliverdin is high enough to obtain reliable measurements of the initial rate in the absence of any biliverdin binding proteins. The initial rate kinetics and the product-inhibition studies are consistent with an ordered sequential mechanism provided the biliverdin concentration was below 20 microM. Above this concentration significant flux occurs through a substrate inhibition pathway involving an enzyme-NAD(P)-biliverdin complex. Chloride is shown to cause a significant activation of the enzyme under certain conditions and this is shown to result from an inability of biliverdin to bind to an enzyme-NAD-chloride complex.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191141     DOI: 10.1016/0167-4838(88)90278-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

1.  The kinetics of ox kidney biliverdin reductase in the pre-steady state. Evidence that the dissociation of bilirubin is the rate-determining step.

Authors:  E Rigney; T J Mantle; F M Dickinson
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

2.  Cloning and overexpression of rat kidney biliverdin IX alpha reductase as a fusion protein with glutathione S-transferase: stereochemistry of NADH oxidation and evidence that the presence of the glutathione S-transferase domain does not effect BVR-A activity.

Authors:  O Ennis; R Maytum; T J Mantle
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

3.  Evidence that biliverdin-IX beta reductase and flavin reductase are identical.

Authors:  F Shalloe; G Elliott; O Ennis; T J Mantle
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

Review 4.  Biliverdin reductase: a target for cancer therapy?

Authors:  Peter E M Gibbs; Tihomir Miralem; Mahin D Maines
Journal:  Front Pharmacol       Date:  2015-06-03       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.